NYU scientists have discovered that cancer cells work together to withstand challenging conditions, revealing new ...
Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
This important study provides solid evidence that glucosylceramide synthase (GlcT), a rate-limiting enzyme for glycosphingolipid (GSL) production, plays a role in the differentiation of intestinal ...
Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...
Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...
Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback